| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 26 | 2021 | 686 | 3.790 |
Why?
|
| Rhabdomyosarcoma | 6 | 2022 | 341 | 1.400 |
Why?
|
| Hospitalization | 5 | 2022 | 2083 | 1.150 |
Why?
|
| Bone Marrow Neoplasms | 5 | 2019 | 132 | 0.950 |
Why?
|
| Child Health | 1 | 2024 | 54 | 0.910 |
Why?
|
| Ownership | 1 | 2023 | 40 | 0.900 |
Why?
|
| Hematology | 1 | 2024 | 104 | 0.860 |
Why?
|
| Hospital Costs | 3 | 2020 | 228 | 0.820 |
Why?
|
| Hospitals, Pediatric | 3 | 2022 | 773 | 0.800 |
Why?
|
| Child | 41 | 2024 | 29154 | 0.770 |
Why?
|
| Drug Costs | 1 | 2021 | 144 | 0.730 |
Why?
|
| Bone Neoplasms | 6 | 2019 | 2576 | 0.720 |
Why?
|
| Life Style | 1 | 2023 | 612 | 0.710 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2020 | 749 | 0.700 |
Why?
|
| Infant | 29 | 2024 | 13310 | 0.700 |
Why?
|
| Health Care Costs | 3 | 2019 | 674 | 0.680 |
Why?
|
| Bacterial Infections | 3 | 2020 | 479 | 0.680 |
Why?
|
| Erwinia | 1 | 2018 | 7 | 0.670 |
Why?
|
| Medicaid | 2 | 2019 | 279 | 0.670 |
Why?
|
| Induction Chemotherapy | 3 | 2020 | 669 | 0.660 |
Why?
|
| Decision Support Techniques | 4 | 2016 | 622 | 0.640 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 1148 | 0.630 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2017 | 31 | 0.630 |
Why?
|
| Parents | 2 | 2023 | 998 | 0.590 |
Why?
|
| Length of Stay | 4 | 2022 | 1900 | 0.590 |
Why?
|
| Diagnosis-Related Groups | 1 | 2016 | 25 | 0.560 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 338 | 0.560 |
Why?
|
| Cost-Benefit Analysis | 5 | 2022 | 945 | 0.560 |
Why?
|
| Child, Preschool | 29 | 2020 | 16273 | 0.540 |
Why?
|
| Drug Therapy | 1 | 2016 | 205 | 0.540 |
Why?
|
| Neoplasms | 9 | 2019 | 15193 | 0.530 |
Why?
|
| Exome | 4 | 2022 | 1239 | 0.510 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 152 | 0.510 |
Why?
|
| Interleukin-2 | 2 | 2008 | 842 | 0.480 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2018 | 442 | 0.480 |
Why?
|
| Mycoses | 1 | 2017 | 386 | 0.480 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 573 | 0.480 |
Why?
|
| Health Services | 1 | 2014 | 105 | 0.470 |
Why?
|
| Cost Savings | 1 | 2014 | 123 | 0.450 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 860 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2021 | 15862 | 0.430 |
Why?
|
| Humans | 66 | 2024 | 261506 | 0.390 |
Why?
|
| Adolescent | 25 | 2024 | 31252 | 0.370 |
Why?
|
| Genome, Human | 1 | 2018 | 1869 | 0.350 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2009 | 62 | 0.350 |
Why?
|
| Bone Marrow | 4 | 2019 | 2358 | 0.340 |
Why?
|
| Fibrosarcoma | 1 | 2009 | 135 | 0.340 |
Why?
|
| Diphosphonates | 1 | 2010 | 262 | 0.330 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2010 | 244 | 0.320 |
Why?
|
| Dactinomycin | 3 | 2021 | 145 | 0.320 |
Why?
|
| Pediatrics | 2 | 2018 | 1141 | 0.310 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2007 | 323 | 0.300 |
Why?
|
| Interleukin-6 | 2 | 2009 | 1038 | 0.300 |
Why?
|
| Sialoglycoproteins | 1 | 2007 | 151 | 0.290 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2007 | 72 | 0.280 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2015 | 882 | 0.280 |
Why?
|
| Lymphokines | 1 | 2007 | 272 | 0.280 |
Why?
|
| Cyclophosphamide | 5 | 2021 | 3001 | 0.270 |
Why?
|
| United States | 9 | 2024 | 15433 | 0.260 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 2796 | 0.250 |
Why?
|
| Imidazoles | 1 | 2010 | 999 | 0.250 |
Why?
|
| Male | 34 | 2020 | 123000 | 0.240 |
Why?
|
| Costs and Cost Analysis | 3 | 2015 | 306 | 0.240 |
Why?
|
| Vincristine | 3 | 2021 | 1511 | 0.240 |
Why?
|
| Safety-net Providers | 1 | 2024 | 53 | 0.230 |
Why?
|
| 3-Iodobenzylguanidine | 2 | 2021 | 31 | 0.230 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 1033 | 0.230 |
Why?
|
| Algorithms | 1 | 2014 | 3890 | 0.230 |
Why?
|
| Iatrogenic Disease | 1 | 2024 | 183 | 0.220 |
Why?
|
| Female | 33 | 2022 | 141928 | 0.220 |
Why?
|
| Ambulatory Care | 2 | 2018 | 554 | 0.220 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 269 | 0.220 |
Why?
|
| Infant, Newborn | 11 | 2022 | 8223 | 0.210 |
Why?
|
| Neutropenia | 2 | 2020 | 968 | 0.210 |
Why?
|
| Surgical Procedures, Operative | 2 | 2016 | 383 | 0.200 |
Why?
|
| Cancer Vaccines | 1 | 2007 | 697 | 0.200 |
Why?
|
| Biopsy | 3 | 2019 | 3443 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 1586 | 0.190 |
Why?
|
| Hospitals, General | 1 | 2020 | 27 | 0.180 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 8865 | 0.170 |
Why?
|
| Dietary Supplements | 1 | 2024 | 558 | 0.170 |
Why?
|
| Diagnostic Imaging | 3 | 2022 | 1162 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2021 | 256 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 266 | 0.170 |
Why?
|
| Biomarkers, Tumor | 4 | 2016 | 10331 | 0.170 |
Why?
|
| Delphi Technique | 1 | 2019 | 210 | 0.170 |
Why?
|
| Treatment Outcome | 9 | 2019 | 32848 | 0.160 |
Why?
|
| Asparaginase | 1 | 2018 | 184 | 0.160 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 140 | 0.150 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2017 | 82 | 0.150 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 5687 | 0.150 |
Why?
|
| Retrospective Studies | 12 | 2024 | 37905 | 0.150 |
Why?
|
| Gene Amplification | 2 | 2017 | 731 | 0.150 |
Why?
|
| Sacrococcygeal Region | 1 | 2016 | 37 | 0.150 |
Why?
|
| Abdominal Neoplasms | 2 | 2012 | 231 | 0.150 |
Why?
|
| Genetic Testing | 2 | 2022 | 1589 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2019 | 583 | 0.140 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2007 | 2104 | 0.140 |
Why?
|
| Young Adult | 9 | 2024 | 21445 | 0.130 |
Why?
|
| Thoracic Neoplasms | 2 | 2012 | 337 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2020 | 661 | 0.130 |
Why?
|
| Genomics | 2 | 2023 | 2738 | 0.130 |
Why?
|
| Bone and Bones | 1 | 2019 | 619 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2024 | 1423 | 0.130 |
Why?
|
| Hospital Records | 1 | 2014 | 11 | 0.130 |
Why?
|
| Critical Illness | 1 | 2020 | 714 | 0.130 |
Why?
|
| Filgrastim | 1 | 2014 | 191 | 0.120 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2014 | 89 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2011 | 1016 | 0.120 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 328 | 0.120 |
Why?
|
| Isotretinoin | 1 | 2014 | 158 | 0.120 |
Why?
|
| Decision Trees | 1 | 2014 | 178 | 0.120 |
Why?
|
| Disease-Free Survival | 6 | 2016 | 10001 | 0.110 |
Why?
|
| Acute Disease | 1 | 2018 | 2422 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1559 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10035 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 3719 | 0.110 |
Why?
|
| Patient Participation | 2 | 2015 | 446 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2010 | 9180 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2015 | 362 | 0.110 |
Why?
|
| Genetic Therapy | 2 | 2011 | 1616 | 0.110 |
Why?
|
| Sex Factors | 1 | 2017 | 2139 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 2 | 2008 | 966 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 543 | 0.110 |
Why?
|
| Aftercare | 1 | 2014 | 259 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 2015 | 748 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2015 | 498 | 0.100 |
Why?
|
| Gangliosides | 1 | 2011 | 95 | 0.100 |
Why?
|
| Endocardial Fibroelastosis | 1 | 2010 | 12 | 0.100 |
Why?
|
| Survivors | 1 | 2016 | 1031 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 14889 | 0.100 |
Why?
|
| Physicians | 1 | 2019 | 882 | 0.100 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 671 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 2 | 2010 | 1290 | 0.090 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 2927 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2015 | 621 | 0.090 |
Why?
|
| Neoplasm, Residual | 4 | 2014 | 1656 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2016 | 1000 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2021 | 2803 | 0.090 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2014 | 489 | 0.090 |
Why?
|
| Valproic Acid | 1 | 2010 | 263 | 0.090 |
Why?
|
| Adoptive Transfer | 1 | 2011 | 446 | 0.090 |
Why?
|
| Recoverin | 1 | 2008 | 22 | 0.090 |
Why?
|
| Mental Disorders | 1 | 2016 | 862 | 0.080 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2008 | 35 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2014 | 1529 | 0.080 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 334 | 0.080 |
Why?
|
| Leg | 1 | 2009 | 226 | 0.080 |
Why?
|
| Neoplasm Proteins | 3 | 2009 | 3230 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2009 | 4844 | 0.080 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 168 | 0.080 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2008 | 145 | 0.080 |
Why?
|
| Incidence | 1 | 2017 | 5673 | 0.080 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 475 | 0.080 |
Why?
|
| Thalidomide | 1 | 2010 | 569 | 0.070 |
Why?
|
| Decision Making | 1 | 2015 | 1287 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 792 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2008 | 1688 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2008 | 1681 | 0.070 |
Why?
|
| Osteopontin | 1 | 2007 | 148 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 143 | 0.070 |
Why?
|
| Hospitals | 2 | 2024 | 485 | 0.070 |
Why?
|
| Remission Induction | 2 | 2010 | 3569 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2014 | 1824 | 0.070 |
Why?
|
| Survival Rate | 4 | 2020 | 12221 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2010 | 502 | 0.070 |
Why?
|
| Risk Factors | 3 | 2018 | 17523 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 846 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 13658 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2007 | 288 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2011 | 1146 | 0.060 |
Why?
|
| Palliative Care | 1 | 2016 | 2037 | 0.060 |
Why?
|
| Cell Line, Tumor | 6 | 2011 | 14551 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 551 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 943 | 0.060 |
Why?
|
| Proteomics | 1 | 2011 | 1380 | 0.060 |
Why?
|
| Genes, p53 | 1 | 2008 | 1090 | 0.060 |
Why?
|
| Cytokines | 2 | 2011 | 2809 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2008 | 1046 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2008 | 986 | 0.060 |
Why?
|
| Population Groups | 1 | 2022 | 42 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2010 | 2054 | 0.050 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 14289 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 4314 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 2 | 2009 | 3976 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2009 | 2819 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2022 | 226 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2014 | 6869 | 0.050 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 77 | 0.050 |
Why?
|
| Prognosis | 4 | 2020 | 21713 | 0.050 |
Why?
|
| Vaccination | 1 | 2007 | 1123 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2020 | 2218 | 0.050 |
Why?
|
| Base Sequence | 2 | 2021 | 4917 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 3981 | 0.050 |
Why?
|
| Biomarkers | 1 | 2011 | 5047 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 371 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 65 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2014 | 6550 | 0.040 |
Why?
|
| Adult | 6 | 2018 | 77950 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2021 | 1471 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 292 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2010 | 2979 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 7548 | 0.040 |
Why?
|
| Busulfan | 1 | 2021 | 764 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 298 | 0.030 |
Why?
|
| Texas | 2 | 2018 | 6311 | 0.030 |
Why?
|
| Cell Proliferation | 4 | 2009 | 7226 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6207 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2292 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 524 | 0.030 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2015 | 12 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 5112 | 0.030 |
Why?
|
| Ontario | 1 | 2015 | 98 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2004 | 1763 | 0.030 |
Why?
|
| Teratoma | 1 | 2016 | 236 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2014 | 155 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 660 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 4988 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 415 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 9244 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 625 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 1052 | 0.030 |
Why?
|
| Recurrence | 2 | 2011 | 4758 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 7551 | 0.030 |
Why?
|
| Etoposide | 1 | 2014 | 870 | 0.030 |
Why?
|
| Outpatients | 1 | 2015 | 462 | 0.030 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2011 | 123 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 823 | 0.020 |
Why?
|
| Acylation | 1 | 2010 | 25 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 208 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2013 | 226 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2013 | 289 | 0.020 |
Why?
|
| Genes, myc | 1 | 2012 | 358 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 4971 | 0.020 |
Why?
|
| Inpatients | 1 | 2015 | 678 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2011 | 374 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2009 | 189 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 384 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7573 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1301 | 0.020 |
Why?
|
| Benzazepines | 1 | 2009 | 108 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 4557 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 259 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 419 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 342 | 0.020 |
Why?
|
| Base Pairing | 1 | 2008 | 68 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 280 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 1363 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2009 | 6150 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 1972 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 709 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 3005 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 460 | 0.020 |
Why?
|
| Cisplatin | 1 | 2014 | 2432 | 0.020 |
Why?
|
| Phenotype | 2 | 2008 | 6295 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2009 | 905 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 1987 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 1555 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1945 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2007 | 392 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2992 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 869 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2005 | 153 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 12873 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 1258 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 825 | 0.020 |
Why?
|
| Apoptosis | 2 | 2009 | 7591 | 0.020 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2004 | 107 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2009 | 1869 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 771 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 1890 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 6682 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 2944 | 0.020 |
Why?
|
| Heterozygote | 1 | 2007 | 1020 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 1489 | 0.010 |
Why?
|
| Histones | 1 | 2010 | 1466 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 2231 | 0.010 |
Why?
|
| Computational Biology | 1 | 2009 | 1271 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2004 | 471 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 493 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 641 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 4938 | 0.010 |
Why?
|
| Immunity | 1 | 2004 | 342 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 1910 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 12926 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 1121 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 6089 | 0.010 |
Why?
|
| Stents | 1 | 2008 | 1096 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 598 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 4804 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2007 | 3536 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 5637 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 5114 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 3639 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 1385 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 3890 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2232 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 3033 | 0.010 |
Why?
|
| Middle Aged | 2 | 2018 | 86204 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 3570 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 1960 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 4892 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 3578 | 0.010 |
Why?
|
| Mice | 2 | 2009 | 34495 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5178 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 5542 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 5767 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2008 | 3341 | 0.010 |
Why?
|
| Animals | 2 | 2009 | 59536 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 7702 | 0.010 |
Why?
|
| Aged | 1 | 2013 | 70117 | 0.000 |
Why?
|
| Mutation | 1 | 2007 | 15179 | 0.000 |
Why?
|